CD274 and neoplasm: Our limited data indicating a positive relation between dMMR status and PD-L1 expression on TCAF may suggest that PD-L1 expression on TCAF may be an additive biomarker for ICI treatment in EC and raise provocative questions about the fact that there are certain immunologic parameters vary between localization of PD-L1 expression between TCAF and tumor cells.